Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL(−1)

Dupilumab is well tolerated and improves clinical outcomes in patients with asthma and high eosinophils (≥500 cells·µL(−1)). Improvements in clinical outcomes correlate with eosinophil counts, demonstrating dupilumab efficacy in those with high eosinophils. https://bit.ly/3Jxvicb

Detalles Bibliográficos
Autores principales: Rabe, Klaus F., Pavord, Ian D., Castro, Mario, Wechsler, Michael E., Daizadeh, Nadia, Kapoor, Upender, Ortiz, Benjamin, Radwan, Amr, Johnson, Robert R., Rowe, Paul J., Deniz, Yamo, Jacob-Nara, Juby A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218240/
https://www.ncbi.nlm.nih.gov/pubmed/35487538
http://dx.doi.org/10.1183/13993003.02577-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218240/
https://www.ncbi.nlm.nih.gov/pubmed/35487538
http://dx.doi.org/10.1183/13993003.02577-2021

Ejemplares similares